AGIO
NASDAQ
US
Agios Pharmaceuticals, Inc. - Common Stock
$35,20
▲ +$1,01
(+2,95%)
Vol. 1.4M
3
Punteggio di Qualità
fail
Ricavi ✗
Utile netto ✗
>IPO ✗
Cap. mercato
$1.6B
ROE
-28,3%
Margine
-895,9%
D/E
0,00
Beta
0,92
52W
$22–$46
Consenso Wall Street
16 analisti · Apr 20265
Acquisto forte
7
Compra
4
Mantieni
0
Vendi
0
Vendita forte
75,0%
Rating Compra
Grafico dei Prezzi
Titoli simili
ADMA
ADMA Biologics Inc
P/E 20,7
$4.3B
RARE
Ultragenyx Pharmaceutical Inc
$2.2B
TYRA
Tyra Biosciences Inc
$1.4B
CLDX
Celldex Therapeutics Inc
$1.8B
SLNO
Soleno Therapeutics Inc
$2.5B
STOK
Stoke Therapeutics Inc
P/E 44,2
$1.8B
VRDN
Viridian Therapeutics Inc
$3.0B
CAPR
Capricor Therapeutics Inc
$1.6B
SION
Sionna Therapeutics Inc
$1.8B
Utili
Tasso di battuta: 75,0%| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Dic 2025 | $-1,99 | $-1,86 | +$0,13 |
| Set 2025 | $-1,94 | $-1,78 | +$0,16 |
| Giu 2025 | $-1,84 | $-1,93 | $-0,09 |
| Mar 2025 | $-1,82 | $-1,55 | +$0,27 |
Ricavi e utili trimestrali
| Trimestre | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Ricavi | — | $10.7M | $8.7M | $12.5M | $12.9M | $20.0M |
| Utile netto | — | -$96.5M | -$89.3M | -$112.0M | -$103.4M | -$108.0M |
Trend fondamentali
| Metrica | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | 43.3% | 43.3% | 43.3% | -28.3% | -28.3% | -28.3% |
| P/E (TTM) | 2.96 | 3.24 | 3.59 | — | — | — |
| Net Margin | -899.4% | 1590.4% | 1590.4% | -895.9% | -895.9% | -895.9% |
| Gross Margin | 86.3% | 88.2% | 88.2% | 87.2% | 87.2% | 87.2% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 14.48 | 14.48 | 14.48 | 13.82 | 13.82 | 13.82 |
Rapporti chiave
ROA (TTM)
-26,4%
P/S (TTM)
35,44
P/B
1,2
EPS (TTM)
$-6,96
CF/Share
$-3,84
Crescita ricavi 3A
-27,2%
52W High
$46,00
52W Low
$22,24
$22,24
Intervallo 52 settimane
$46,00
Salute finanziaria
Flusso di cassa libero
-$97.3M
Debito netto
-$48.9M
Liquidità
$89.1M
Debito totale
$40.2M
Aggiornato al Dic 31, 2025
Як AGIO виглядає на тлі конкурентів у Biotechnology?
Група порівняння: Micro-cap Biotechnology (All) · 528 компаній
Оцінка AGIO vs аналоги Biotechnology
P/E
—
▼
0%
sotto
peer
(18,8)
vs Peer
vs Settore
Sottovalutato
P/S
35,4
▲
176%
sopra
peer
(12,9)
vs Peer
vs Settore
Più costoso
P/B
1,2
▼
51%
sotto
peer
(2,5)
vs Peer
vs Settore
Sottovalutato
Дивідендна дохідність
—
▼
0%
sotto
peer
(0,0%)
vs Peer
vs Settore
Rendimento basso
Прибутковість AGIO vs аналоги Biotechnology
ROE
-28,4%
▲
58%
sopra
peer
(-67,3%)
vs Peer
vs Settore
Top livello
Net margin
-895,9%
▼
212%
sotto
peer
(-286,8%)
vs Peer
vs Settore
Debole
Валова маржа
87,2%
▲
11%
sopra
peer
(78,6%)
vs Peer
vs Settore
Debole
ROA
-26,4%
▲
43%
sopra
peer
(-46,7%)
vs Peer
vs Settore
Top livello
Фінансове здоровʼя AGIO vs аналоги Biotechnology
D/E ratio
0,0
▼
0%
sotto
peer
(0,0)
vs Peer
vs Settore
Debito basso
Поточна ліквідність
13,8
▲
211%
sopra
peer
(4,4)
vs Peer
vs Settore
Liquidità forte
Beta
0,9
▼
5%
sotto
peer
(1,0)
vs Peer
vs Settore
Meno volatile
Радар фундаменталів AGIO
AGIO
Mediana peer
Industria
AGIO прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio